EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Methotrexate-based PROTACs as DHFR-specific chemical probes

Sandeep Rana, Patricia Dranchak, Jayme L Dahlin, Laurence Lamy, Wenqing Li, Erin Oliphant, Jonathan H Shrimp, Girish H Rajacharya, Ravi Tharakan, David O Holland, Apryl S Whitten, Kelli M Wilson und 5 weitere

Cell Chemical Biology · 2024

DOI: 10.1016/j.chembiol.2023.09.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Chemical Biology, 2024. Verfasst von Sandeep Rana und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD 20850, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Folic Acid Antagonists, Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NCI NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methotrexate (MTX) is a tight-binding dihydrofolate reductase (DHFR) inhibitor, used as both an antineoplastic and immunosuppressant therapeutic. MTX, like folate undergoes folylpolyglutamate synthetase-mediated γ-glutamylation, which affects cellular retention and target specificity. Mechanisms of MTX resistance in cancers include a decrease in MTX poly-γ-glutamylation and an upregulation of DHFR. Here, we report a series of potent MTX-based proteolysis targeting chimeras (PROTACs) to investigate DHFR degradation pharmacology and one-carbon biochemistry. These on-target, cell-active PROTACs show proteasome- and E3 ligase-dependent activity, and selective degradation of DHFR in multiple cancer cell lines. By comparison, treatment with MTX increases cellular DHFR protein expression. Importantly, these PROTACs produced distinct, less-lethal phenotypes compared to MTX. The chemical probe set described here should complement conventional DHFR inhibitors and serve as useful tools for studying one-carbon biochemistry and dissecting complex polypharmacology of MTX and related drugs. Such compounds may also serve as leads for potential autoimmune and antineoplastic therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsFolic Acid AntagonistsNeoplasmsHumansCarbonMethotrexateProteolysis Targeting ChimeraTetrahydrofolate Dehydrogenase

Stichwörter der Autor:innen

DHFR-HiBiTMTX-Cy5PROTACantifolatesdihydrofolate reductasemethotrexateone-carbon metabolismtargeted protein degradationthymidylate synthase

Substanzen

Antineoplastic AgentsCarbonFolic Acid AntagonistsMethotrexateProteolysis Targeting ChimeraTetrahydrofolate Dehydrogenase

Autor:innen und Institutionen

  • Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD 20850, USA.
  • Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD, USA.
  • Department of Oncology Science, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
  • Department of Oncology Science, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA; OU Health Stephenson Center, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
  • Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD 20850, USA. Electronic address: bantukallug@mail.nih.gov.
  • Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD 20850, USA; Metabolic Medicine Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA.…

Förderung

  • NCATS NIH HHS
  • NCI NIH HHS
  • Intramural NIH HHS
  • National Institutes of Health
  • U.S. Department of Health and Human Services
  • National Center for Advancing Translational Sciences
  • National Cancer Institute

Zitieren

APA

Rana, S., Dranchak, P., Dahlin, J. L., Lamy, L., Li, W., Oliphant, E., Shrimp, J. H., Rajacharya, G. H., Tharakan, R., Holland, D. O., Whitten, A. S., Wilson, K. M., Singh, P. K., Durum, S. K., Tao, D., Rai, G., & Inglese, J. (2024). Methotrexate-based PROTACs as DHFR-specific chemical probes. Cell Chemical Biology. https://doi.org/10.1016/j.chembiol.2023.09.014

Vancouver

Rana S, Dranchak P, Dahlin JL, Lamy L, Li W, Oliphant E, et al. Methotrexate-based PROTACs as DHFR-specific chemical probes. Cell Chemical Biology. 2024. doi:10.1016/j.chembiol.2023.09.014

BibTeX
@article{Rana2024,
  author = {Rana, Sandeep and Dranchak, Patricia and Dahlin, Jayme L and Lamy, Laurence and Li, Wenqing and Oliphant, Erin and Shrimp, Jonathan H and Rajacharya, Girish H and Tharakan, Ravi and Holland, David O and Whitten, Apryl S and Wilson, Kelli M and Singh, Pankaj K and Durum, Scott K and Tao, Dingyin and Rai, Ganesha and Inglese, James},
  title = {Methotrexate-based PROTACs as DHFR-specific chemical probes},
  journal = {Cell Chemical Biology},
  year = {2024},
  doi = {10.1016/j.chembiol.2023.09.014}
}
Kostenlos starten →